{
event: "article_read",
name: `Teri-Pro Study`,
author: ``,
tags: `Multiple Sclerosis | Multiple Sclerosis`,
publication_date: ``,
interaction_type: "content"
}
Teri-Pro Study
Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Related articles
MAT-BH-2100670-V1, September 2021